2,912 companies
Ardmore Fund 2, LLC
North Carolina
Ardmore Fund 3, LLC
North Carolina
Ardmore Gibsonville, LLC
North Carolina
Ardmore Huntersville, LLC
North Carolina
ArenaCX, Inc.
North Carolina
Arep BRSC, LLC
North Carolina
Areteia Therapeutics, Inc.
North Carolina
ARGS
Argos Therapeutics Inc
The ADAPT trial is a randomized, multicenter, open label trial comparing combination therapy with rocapuldencel-T and sunitinib (or another targeted therapy) to monotherapy with sunitinib (or another targeted therapy) for the treatment of newly diagnosed metastatic renal cell carcinoma (mRCC). A total of 462 previously untreated patients were enrolled in the ADAPT trial and randomized 2:1 between combination treatment with rocapuldencel-T and sunitinib (combination arm) vs.
North Carolina
NASDAQ
Aries USA, Inc.
North Carolina
Arjuna Capital
North Carolina
Armor Investment Advisors, LLC
North Carolina
Arpio, Inc.
North Carolina
Arrevus, Inc.
North Carolina
Arrington Aleworks, LLC
North Carolina
Arrivo BioVentures, LLC
North Carolina
Artful Asheville, LLC
North Carolina
Asana Global Select Fund, LP
North Carolina
Asana Partners Fund II REIT 1, LLC
North Carolina
Asana Partners Fund II REIT 13, LLC
North Carolina
Asana Partners Fund II REIT 14, LLC
North Carolina